Article Abstract

Current evidence for active surveillance for intermediate risk prostate cancer: editorial on comparison of pathological and oncologic outcomes in "favorable risk" GS 3+4 and low risk GS6 prostate cancer by Gearman et al., Journal of Urology

Authors: Chirag G. Gordhan, Michael J. Whalen

Abstract

Active surveillance is now endorsed as the preferred treatment approach for patients with National Comprehensive Cancer Network (NCCN) very-low and low risk prostate cancer.